- Home
- HPS vs ATXS Comparison
HPS vs ATXS Comparison
Compare HPS & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPS
- ATXS
- Stock Information
- Founded
- HPS 2003
- ATXS 2008
- Country
- HPS United States
- ATXS United States
- Employees
- HPS N/A
- ATXS N/A
- Industry
- HPS Investment Managers
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- HPS Finance
- ATXS Health Care
- Exchange
- HPS Nasdaq
- ATXS Nasdaq
- Market Cap
- HPS 475.4M
- ATXS 424.4M
- IPO Year
- HPS N/A
- ATXS 2015
- Fundamental
- Price
- HPS $15.58
- ATXS $7.52
- Analyst Decision
- HPS
- ATXS Buy
- Analyst Count
- HPS 0
- ATXS 6
- Target Price
- HPS N/A
- ATXS $33.00
- AVG Volume (30 Days)
- HPS 58.4K
- ATXS 436.6K
- Earning Date
- HPS 01-01-0001
- ATXS 11-12-2025
- Dividend Yield
- HPS 8.62%
- ATXS N/A
- EPS Growth
- HPS N/A
- ATXS N/A
- EPS
- HPS N/A
- ATXS N/A
- Revenue
- HPS N/A
- ATXS N/A
- Revenue This Year
- HPS N/A
- ATXS N/A
- Revenue Next Year
- HPS N/A
- ATXS N/A
- P/E Ratio
- HPS N/A
- ATXS N/A
- Revenue Growth
- HPS N/A
- ATXS N/A
- 52 Week Low
- HPS $11.79
- ATXS $3.56
- 52 Week High
- HPS $15.40
- ATXS $12.52
- Technical
- Relative Strength Index (RSI)
- HPS 73.09
- ATXS 55.75
- Support Level
- HPS $15.24
- ATXS $6.95
- Resistance Level
- HPS $15.43
- ATXS $7.48
- Average True Range (ATR)
- HPS 0.16
- ATXS 0.42
- MACD
- HPS 0.01
- ATXS -0.01
- Stochastic Oscillator
- HPS 85.38
- ATXS 65.35
About HPS John Hancock Preferred Income Fund III Preferred Income Fund III
John Hancock Preferred Income Fund III is a closed-end, diversified management investment company. Its investment objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve the objectives by investing a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. The portfolio composition of the company consists of the U.S. preferred securities, foreign preferred securities, common stocks, corporate bonds, and the short-term investments.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.